Sarcopenia is a progressive age-related generalized reduction in skeletal muscle mass,decreased skeletal muscle strength,and/or reduced somatic function.Recent epidemiological surveys in China have shown that the prevalence of sarcopenia among individuals aged 60 and above ranges from 5.7％to 23.9％.This condition increases the risk of falls and fractures,thereby exacerbating the burden on families and society.Currently,there are no effective pharmacological treatments for sarcopenia.Muscle and bone show significant commonalities in development,growth,ag-ing,and many diseases,and sarcopenia often occurs with osteoporosis.Zoledronic acid is one of the more widely used an-ti-osteoporosis drugs in clinical practice,and it acts mainly by inhibiting famesyl pyrophosphate synthase in the meval-onate metabolic pathway.Zoledronic acid not only maintains bone integrity,but also exerts muscle-promoting effects in a variety of situations.This article reviews the effects of zoledronic acid on sarcopenia and the potential mechanisms in-volved to provide new ideas for the future treatment of sarcopenia.
SarcopeniaZoledronic acidMolecular mechanisms of pharmacological actionReview
维普
万方数据
